The changes will aim to make it easier to gain approval and to run clinical trials in the UK
Dupixent is now the first and only targeted medicine in the EU for this patient population
If approved, the test could streamline the journey to diagnosis for more patients
Plaque psoriasis accounts for around 80-90% of the 125 million psoriasis cases worldwide
There is currently only one approved biologic treatment for the inflammatory skin disease